Antibody‐mediated inhibition of tissue‐type plasminogen activator binding to the low‐density lipoprotein receptor‐related protein 1 as a potential beneficial modulator for stroke therapy

Abstract

AbstractThe acute ischemic stroke therapy of choice is the application of Alteplase, a drug containing the enzyme tissue‐type plasminogen activator (tPa) which rapidly destabilizes blood clots. A central hallmark of stroke pathology is blood‐brain barrier (BBB) breakdown associated with tight junction (TJ) protein degradation, which seems to be significantly more severe under therapeutic conditions. The exact mechanisms how tPa facilitates BBB breakdown are not entirely understood. There is evidence that an interaction with the lipoprotein receptor‐related protein 1 (LRP1), allowing tPa transport across the BBB into the central nervous system, is necessary for this therapeutic side effect. Whether tPa‐mediated disruption of BBB integrity is initiated directly on microvascular endothelial cells or other brain cell types is still elusive. In this study we could not observe any changes of barrier properties in microvascular endothelial cells after tPa incubation. However, we present evidence that tPa causes changes in microglial activation and BBB breakdown after LRP1‐mediated transport across the BBB. Using a monoclonal antibody targeting the tPa binding sites of LRP1 decreased tPa transport across an endothelial barrier. Our results indicate that limiting tPa transport from the vascular system into the brain by coapplication of a LRP1‐blocking monoclonal antibody might be a novel approach to minimize tPa‐related BBB damage during acute stroke therapy.